Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.
The editors at FiercePharma in the last 18 months have found ourselves writing a fair number of stories about animal health operations. Many of the companies we cover have animal health units and the success, or lack thereof, for those is a big deal for these companies and their investors.
Doctors aren't the only ones to fall prey to free lunches and fuzzy promotional talks. Medical students who spend more time with& pharma reps are more likely to dole out brand-name products, and less likely to rely on evidence when choosing which drugs to use, Medscape reports.
Any brand managers eager to jump into Twitter as soon as the FDA gave the go-ahead? No such luck. Last week's social media guidance on risk disclosures may have cleared up some of the regulatory fog, but in this case, clarity isn't a positive.
I'm not a doctor, but I play one on TV. That approach has put pharma in the doghouse before. But now, here's a new question. What about, "I'm not a patient, but I play one in a promo campaign for doctors"?
It's a tale of two statin drugs and their attempts to keep market share--or build it, as the case may be. Pfizer rolled out a new version of its Lipitor copay discount program, and this time, it applies to patients covered via certain U.S. government programs.
New sales models are trendy in Big Pharma. Actually, they're de rigueur: With thousands fewer drug reps on the street these days, and many doctors turning reps away, companies have had to turn to new ways of promoting their products. Plus, all those pesky Department of Justice settlements make the old hard sell seem sketchy.
FDA officials are having a rethink on free speech--and that could end with an about-face on off-label marketing.
China is coming down hard on GlaxoSmithKline's local operation. After a months-long bribery probe, Chinese police have slapped Glaxo's former country chief--Mark Reilly, a Brit--and two other top Chinese executives with several counts of bribery.
When Big Pharma starts talking about big buyouts, the sales and marketing departments start chattering about their jobs. Last week's Novartis-plus-GlaxoSmithKline cancer deal is one prime example. Another, bigger one: Pfizer's proposed $100-billion-or-so buyout of AstraZeneca.